
Kluwer Patent Blog

Alendronic Acid, Federal Supreme Court (Bundesgericht), 4 March 2011

Andri Hess (Homburger AV) · Wednesday, November 2nd, 2011

Patentability of an invention is not excluded by the mere fact that the only feature of the patent claim not comprised in the state of the art is a dosage regime.

Click [here](#) for the full text of this case.

A [full summary](#) of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change



This entry was posted on Wednesday, November 2nd, 2011 at 5:26 pm and is filed under [Case Law](#), [Second Medical Use](#), [Switzerland](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.